同时检测多种肿瘤标志物对于癌症的准确诊断和早期治疗具有重要意义。电化学同质生物传感策略已被证明具有灵敏度高、无需电极修饰等优点，但在同时检测多种肿瘤标志物领域仍然是一个挑战。 ER、PR、HER2 和 Ki67 蛋白是乳腺癌临床分子分型的标准生物标志物。精确、灵敏且同时检测这四种生物标志物对于乳腺癌的分子分型非常重要，有助于制定个性化治疗计划。在本研究中，我们开发了一种基于金属离子/SiO2NPs/磁珠的电化学均质电化学生物平台，用于通过单个电极在一个系统中直接检测人血清中的四种生物标志物并同时诊断10种乳腺癌。电化学生物平台检测时间短，可达140 min；但目前临床组织检测时间大约需要1周。此外，电化学生物平台选择性检测 0-1000 pg/mL 范围内的 HER2、ER、Ki67 和 PR，检测限分别为 2、1.8、10.36 和 1.33 pg/mL。

Simultaneous detection of multiple tumor markers is of great significance for an accurate diagnosis and early treatment of cancer. Electrochemical homogeneous biosensing strategies have been shown to have advantages, such as high sensitivity and no electrode modification, but they are still a challenge in the field of simultaneous detection of multiple tumor markers. The ER, PR, HER2, and Ki67 proteins are the standard biomarkers for the clinical molecular typing of breast cancer. Precise, sensitive, and simultaneous detection of these four biomarkers is of great importance in the molecular typing of breast cancer, which helps in the creation of personalized treatment plans. In the present study, we developed an electrochemical homogeneous electrochemical bioplatform based on metal ions/SiO2NPs/magnetic beads for detection of the four biomarkers and simultaneous diagnosis of the 10 types of breast cancer directly in human serum at one system by a single electrode. The electrochemical bioplatform has a short detection time of 140 min; however, the current clinical tissue testing time takes about 1 week. Also, the electrochemical bioplatform selectively detects HER2, ER, Ki67, and PR in a range of 0-1000 pg/mL with detection limits of 2, 1.8, 10.36, and 1.33 pg/mL, respectively.